The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

The findings suggest that the HER2DX assay could help clinicians decide on the appropriate use of chemotherapy in older patients, study researchers wrote.

The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “ HER2DX in older ...

The bispecific HER2-directed antibody-drug conjugate (ADC) TQB2102 has demonstrated robust antitumor activity and a positive safety profile in the phase 2 TQB2102-II-01 trial (NCT06198751), showing ...

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class ...